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Background: Src homology 3 (SH3) domains bind sequences bearing the
consensus motif PxxP (where P is proline and x is any amino acid), wherein
domain specificity is mediated largely by sequences flanking the PxxP core.
This specificity is limited, however, as most SH3 domains show high ligand
cross-reactivity. We have recently shown that diverse N-substituted residues
(peptoids) can replace the prolines in the PxxP motif, yielding a new source of
ligand specificity.
Results: We have tested the effects of combining multiple peptoid
substitutions with specific flanking sequences on ligand affinity and specificity.
We show that by varying these different elements, a ligand can be selectively
tuned to target a single SH3 domain in a test set. In addition, we show that by
making multiple peptoid substitutions, high-affinity ligands can be generated
that completely lack the canonical PxxP motif. The resulting ligands can
potently disrupt natural SH3-mediated interactions. 
Conclusions: Peptide–peptoid hybrid scaffolds yield SH3 ligands with markedly
improved domain selectivity, overcoming one of the principal challenges in
designing inhibitors against these domains. These compounds represent
important leads in the search for orthogonal inhibitors of SH3 domains, and can
serve as tools for the dissection of complex signaling pathways.
Introduction
Eukaryotic signal transduction involves the assembly of
transient protein–protein complexes. The formation of
these complexes is mediated by modular protein–protein
interaction domains such as SH2, SH3 and PDZ domains
[1,2]. An important goal in chemical biology is the design
of small molecule ligands that might selectively disrupt
these interactions. Such inhibitors would be powerful
tools in the mechanistic dissection of complex signaling
pathways, and could serve as therapeutic agents in dis-
eases caused by signaling-based defects. 
Src homology 3 (SH3) domains are found in numerous
signaling proteins and are attractive targets for drug
design as their interactions have been implicated in a
number of diseases such as cancer, osteoporosis and
inflammation [3,4]. SH3 domains recognize peptide
sequences containing the core binding motif PxxP
(where P is proline and x is any amino acid) [5].
Residues that flank the PxxP motif provide additional
binding energy and most of the selectivity involved in
recognition: for example, the SH3 domains from the
protein Grb2 require an arginine residue to be carboxy-
terminal to the PxxP core (consensus motif: PxxPxR) for
binding [6–10]. 
SH3 domains, however, have proved to be difficult targets
for drug design. First, most SH3 ligand interactions are of
relatively low affinity, with dissociation constants ranging
from 1 to 100 µM. Second, and perhaps most problematic,
SH3 ligands show high cross-reactivity with several SH3
domains. For example, the SH3 domains from Grb2, Crk,
Hck, Src and others all show overlapping interaction with
peptides bearing flanking basic residues (consensus motif:
PxxPxR/K) [6–10]. How then can one obtain SH3 ligands
with improved affinity and selectivity?
Previously, the most successful efforts to increase SH3
ligand specificity have focused primarily on replacing
sequences flanking the PxxP motif with natural or non-
natural moieties [8,11–13]. These flanking residues inter-
act with the so-called specificity pocket of the SH3 domain
fold, which is composed of the variable ‘RT’ and ‘n-Src’
loops. Although these efforts have been successful, they
have not eliminated cross-reactivity between domains. In
contrast, little effort has been expended on altering the
core PxxP motif, which is common to all SH3 ligands and is
thus thought to be a poor source of specificity. 
Recently, however, we reported a promising strategy for
the design of improved SH3 ligands that focuses on the
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PxxP core [14]. This strategy is based on the unusual
mechanism of SH3 domain recognition. These domains
recognize proline solely because it is substituted on the
backbone amide nitrogen. Thus, SH3 domains select
proline because it is the only endogenous N-substituted
amino acid. By focusing on a chemical property that is
orthogonal to other naturally occurring amino acids rather
than optimizing complementarity to the full proline
sidechain, these domains can recognize their ligands with
high discrimination but low affinity, properties that are
advantageous in signaling interactions.
As a result of this mechanism, N-substituted glycines, or
peptoids [15,16], function as ideal proline mimetics as
they maintain the required backbone N-substitution
pattern. Moreover, the diversity of the N-substituted
peptoid sidechains can potentially provide improved
complementarity to the SH3 surface. Thus a hybrid
peptide–peptoid backbone, in which prolines of the PxxP
motif are replaced with peptoids, can function as a scaf-
fold from which different sidechains can be sampled for
improvement in affinity and specificity. Peptoids have
added advantages in that they are modular and easy to
synthesize [16], are protease resistant [17] and are more
membrane permeable [18] than natural amino acids.
We previously screened a small aliphatic and aromatic
hybrid peptide–peptoid library and identified several of
the most promising inhibitors against SH3 domains iden-
tified so far (dissociation constant, Kd = 40 nM) [14].
These first generation inhibitors show up to a 100-fold
improvement in affinity and selectivity over natural pep-
tides. In contrast, most other peptide and non-peptidic
libraries have failed to yield ligands that bind signifi-
cantly better than the wild-type peptide [19–24]. 
Here we focus on how peptoid substitutions can be used to
enhance ligand selectivity. We have explored the effects of
combining peptoid substitutions with various flanking
sequences on the energetics of SH3 ligand discrimination.
First, by screening a new, more chemically diverse
peptide–peptoid library, we have identified individual
peptoid residues that give rise to significantly improved
affinity and specificity. Second, by making multiple
peptoid substitutions, we have generated an SH3 ligand
that completely lacks the PxxP motif. Finally, starting with
a parental peptide that displays cross-reactive binding to a
test set of three SH3 domains, we show that, by combining
multiple peptoid substitutions with specific flanking
sequences, we can fine tune specificity so that binding is
only observed for a single SH3 domain in the test set.
These new ligands can out-compete natural SH3 interac-
tions, as shown by the inhibition of the Crk–Abl interaction
and the activation of the Src-family kinase Hck. These data
show that the PxxP core of SH3 ligands can be varied con-
siderably, and that it is an untapped source of specificity.
These data also show that cross-reactivity — previously one
of the principal obstacles in the design of selective
inhibitors against SH3 interactions — can be overcome by
combining different specificity elements, spread through-
out the entire SH3 ligand.
Results
Library synthesis and screening
A library of 12 new hybrid peptide–peptoid compounds
was synthesized and screened for binding to three differ-
ent SH3 domains. Single peptoid substitutions were made
within a 12-residue peptide derived from the protein Sos
(Figure 1). Whereas previous libraries were predomi-
nantly composed of hydrophobic aliphatic and aromatic
sidechains, peptoids of the current library were chosen for
diversity of shape and chemical properties. We concen-
trated mainly on sidechains containing oxygen and nitro-
gen, reasoning that these groups could interact with
residues on the surface of the SH3 domain through polar
interactions, which might potentially give rise to higher
specificity. We tested this library against SH3 domains
from three proto-oncoproteins, Crk, Src and Grb2 (amino-
terminal domain, N-Grb2), because they all bind the wild-
type Sos peptide with similar affinities (Kd = 6 µM, 25 µM
and 5 µM, respectively) [14]. Binding of the ligands to the
three SH3 domains was assayed by measuring perturba-
tion of tryptophan fluorescence upon binding.
Improved selectivity and affinity
The higher chemical diversity of this new library is
reflected in the larger range of affinities observed for SH3
binding. Whereas most of the compounds in the previous
libraries bound with similar affinities to the wild-type
peptide, most peptoid compounds in this library showed
either marked increases or decreases in affinity (Figure 2).
As expected, most peptide–peptoid compounds bound
with reduced affinity compared with wild-type peptide.
Those with peptoid sidechains containing positively
charged amino groups showed the least favorable binding. 
From this library we identified two compounds that showed
significant improvement in affinity and specificity compared
with wild-type peptide. Compound 4, which contains a
difluorobenzyl (Ndfb) sidechain, bound N-Grb2 with a Kd of
300 nM, a 1.67 kcal/mol increase in binding energy over the
wild-type peptide. More markedly, compound 5, which con-
tains a dimethoxybenzyl (Ndmb) sidechain, bound N-Grb2
with a Kd value of ~30 nM. This represents more than 100-
fold increase in affinity (∆∆G ≤ –3 kcal/mol). The improve-
ments were specific to N-Grb2, as both compounds showed
slight decreases in affinity when tested against Crk and Src.
As a result, compound 5 showed a more than 300-fold speci-
ficity for N-Grb2 compared with Crk, and close to a 1500-
fold specificity compared with Src (Figure 2). The
improvement in affinity and specificity is remarkable, given
that they result from a one-residue substitution. 
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Two other compounds (7 and 13) showed significant
improvement in specificity for the SH3 domain of Crk.
Both compounds had slight decreases in affinity for Crk,
but they had much larger decreases for N-Grb2 and Src
SH3 domains. This result illustrates the important
concept that specificity can be achieved not only by
increasing affinity to a particular target domain, but also by
decreasing affinity to competing domains.
The PxxP core can be completely replaced by nonproline
residues
From this and previous work, we have found that the pro-
lines of the PxxP motif can be individually replaced by pep-
toids to yield improvements in affinity [14]. Here, we have
synthesised compounds in which both prolines of the PxxP
motif have been replaced by peptoids (Table 1). To our
knowledge, this is the first report in which the entire con-
sensus motif has been replaced. The doubly substituted
peptoid ligands bind as well as or better than wild-type pep-
tides. Compound 14, for example, bound to N-Grb2 with a
Kd of 100 nM, a 50-fold improvement over the wild-type
peptide (∆∆G = –2.3 kcal/mol). Notably, most double
peptoid substitutions do not show simple additivity in the
energy of binding. For example, substitution of the N-(S)-
phenylethyl peptoid (Nspe) [14] at the P–1 site resulted in
a~100-fold increase in affinity when tested against N-Grb2,
and substitution of the same peptoid at the P2 site resulted
in a fivefold increase. The doubly substituted peptoid (com-
pound 14) showed only a 50-fold increase in affinity
(Table 1). This was the case for most of the doubly substi-
tuted peptoids tested (compounds 14–17), wherein double
substitution resulted in an affinity intermediate between
the affinities of the two singly substituted sites. 
This lack of additivity suggests that there is conforma-
tional coupling between the two sites requiring N-substitu-
tion. Indeed, the crystal structures of several peptoid–SH3
complexes show that replacement of one proline with
bulky peptoid sidechains can result in a displacement of
the ligand backbone atoms relative to the SH3 surface of
up to 1.5 Å [14]. Thus, it is not surprising that sidechain
preferences at the first site will depend on the exact substi-
tution at the second site. These findings suggest that the
most effective peptoid replacements might be obtained by
combinatorially varying the two positions simultaneously.
We also tested the effects of the removing other proline
residues in the ligands that were not part of the PxxP core.
SH3 ligands bind in the poly-proline type II (PPII) helical
conformation, and noncritical prolines might be involved
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Figure 1
Design of hybrid peptide–peptoid library.
(a) Representation of a bound SH3 ligand
showing the backbone requirements for SH3
recognition [11]. Designation of ligand-binding
sites from Yu et al. [40]. (b) Synthesis scheme
for peptide–peptoid hybrid library. Peptoid
substitutions in the current library were made at
the second proline of the PxxP motif (P–1 site,
arrow) in a 12-residue peptide derived from the
protein Sos. Biochemical and crystallographic
data indicate that peptoid substitution locks the
ligand into only one possible binding
registration, such that the peptoid sidechain
must bind at the site that accepts
N-substitution (P–1) [11]. In any other binding
registration, the peptoid sidechain would be
placed at a site that requires Cα-substitution,
which is disallowed in SH3 recognition.
Requires C-substituted residue (proline or normal amino acid)
Requires N-substituted residue (proline or peptoid)
Flanking basic residue
(a)
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in maintaining the PPII helical scaffold [6,14]. Mutations
of these prolines, even those that do not contact the SH3
surface, can result in a modest decrease in affinity [14]. In
compound 18, we replaced three of the five prolines in the
wild-type peptide with either peptoids or natural amino
acids, and in compound 19 we replaced four of the five
prolines. These compounds bound with an affinity close
to that of the wild-type (Table 1). Compound 19 contains
no PxxP motifs, only one proline, and no longer resembles
a canonical SH3 ligand. Nonetheless, compound 19 still
binds N-Grb2 and Src with wild-type affinity (Figure 3).
This finding shows very clearly that the cyclic proline
sidechain and its resulting conformational constraints are
unnecessary for SH3 domain recognition.
Tuning SH3 domain selectivity
SH3 domains contain a ‘specificity pocket’ that is formed
by the RT and n-Src loops proximal to the main PxxP-
binding site. This pocket is often lined with acidic residues
that interact with a basic residue flanking the PxxP motif on
the ligand. Several groups have shown that individual SH3
domains have unique preferences for flanking sequences.
For example, the Crk SH3 domain prefers a lysine as the
flanking basic residue (PxxPxK) [8,9,13], whereas the Src
SH3 prefers the sequence PxxPxRNRPRA [7,22]. 
We wanted to test whether affinity and specificity can be
enhanced by combining specific flanking sequences with
peptoid substitutions. On the basis of other studies, we syn-
thesized two high-affinity peptides specific to Src [7] and
Crk [13] and measured their affinities for the SH3 domains
in the test set. Compound 20, which contains a Src-specific
flanking sequence, bound to Src SH3 with a Kd of 0.3 µM
(80-fold higher affinity than that of the Sos peptide). The
peptide with a Crk-specific flanking sequence (compound
22) bound to Crk SH3 with a Kd of 20 nM (300-fold higher
affinity than that of the Sos peptide; Figure 4a,b). Signifi-
cantly, compound 22 was highly specific for Crk SH3,
466 Chemistry & Biology 2000, Vol 7 No 7
Figure 2
Structure and affinity of hybrid peptide–
peptoid library. Effects of peptoid replacement
at the second proline-requiring site (site P–1)
of SH3 ligand tested against N-Grb2, Crk and
Src SH3 domains. The changes in free energy
relative to the wild-type Sos peptide are color
coded according to ∆∆G (red, favorable; blue,
unfavorable). Kd values were determined by
fluorescence perturbation and reported values
are the averages of at least two independent
experiments. For low-affinity compounds
wherein the change in fluorescence (I0)
does not approach the maximum change in
fluorescence (I
∞
) even at the highest ligand
concentrations, the dissociation constants
were derived using the I
∞
for the wild-type
Sos peptide and are therefore presented
as estimates.
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showing more than 1000-fold selectivity over N-Grb2 and
4000-fold selectivity over Src (Figure 4b).
We then made selected peptoid substitutions in the
context of these Src-specific and Crk-specific peptide back-
grounds (Table 1). Substitution of the Nspe peptoid at site
P–1 in the Src-specific peptide background (compound 21)
and at site P2 in the Crk-specific peptide background (com-
pound 23) resulted in further increases in affinity. In the
case of Crk, we estimate the Kd of compound 23 to be 8 nM
(see the Materials and methods section), to our knowledge
the tightest interaction reported for an SH3 domain.
Nonetheless, although both compounds 22 and 23
showed a remarkably high preference for the Crk SH3,
they still showed weaker but significant binding to the
N-Grb2 and Src SH3 domains. Thus, these compounds
are not truly orthogonal and may not be ideal inhibitors
for selectively blocking the interactions of one SH3
domain. Given that the intracellular concentrations of
Crk and other SH3 containing proteins are thought to be
fairly high (0.1–10 µM, especially at specific cellular
sites), stoichiometric inhibition of these adapter proteins
may require greater than micromolar concentrations of
inhibitor. At these high concentrations, the effective
in vivo selectivity of a low nanomolar affinity inhibitor for
Crk would be greatly diminished, because the concentra-
tion would approach or exceed the dissociation constants
of the inhibitor for other competing SH3 interactions. 
Ideal SH3 inhibitors should have orthogonal binding prop-
erties — that is, they should bind to only one SH3 domain
even under conditions of high concentration — if they are
to be effective in vivo. We therefore wanted use peptoid
substitutions to generate ligands that could bind Crk with
at least micromolar affinities, but that showed no
detectable binding (Kd > 1 mM) to either Src or Grb2. 
Looking at the data from the library screen, we saw that
substitution of the Nnme peptoid at site P–1 resulted in a
modest decrease in affinity for Crk SH3 but a signifi-
cantly larger decrease in affinity for N-Grb2 and Src. Sub-
stitution of this peptoid into the Crk peptide background
(compound 24) shifted the Kd for Crk to 0.5 µM, but more
importantly it increased the Kd for N-Grb2 to close to
1 mM and abrogated detectable binding to Src
(Figure 4c). A doubly substituted compound (25) with the
Nspe peptoid at the P2 site and the Nnme peptoid at the
P–1 site bound to Crk with a Kd of 2 µM, but showed no
detectable binding to either N-Grb2 or Src (Figure 4d).
Thus, by combining specific flanking sequences and mul-
tiple peptoid substitutions, we have generated a ligand
with orthogonal selectivity for a single SH3 domain
within the test set. These results show that it is possible,
in principle, to exploit the multiple specificity elements
in SH3 ligands to generate orthogonal inhibitors.
Potent inhibition of the Crk–Abl interaction
To determine the effectiveness of the Crk-specific
peptide–peptoid ligands in disrupting natural Crk SH3
interactions, we determined their abilities to inhibit the
interactions between Crk and the kinase Abl. Crk is a
well-characterized substrate of the Abl nonreceptor
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Table 1
Values in parentheses are the dissociation constants for single
substitutions of the peptoid residues shown at sites P2 and P–1,
respectively, as determined previously [11]. Important residue
changes are highlighted in red. No binding means there was no
significant changes in fluorescence even at the highest ligand
concentrations (0.8–1 mM). 
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tyrosine kinase. The amino-terminal SH3 domain of
CrkII interacts with proline-rich sequences in the
carboxy-terminal region of Abl in vitro and in vivo
[25,26], leading to the phosphorylation of Crk on Tyr221
by Abl. Phosphorylation might regulate the ability of
Crk to engage in downstream signaling interactions [27]. 
In order to assay for inhibition of the Crk–Abl inter-
action, a fusion protein of glutathione-S-transferase
(GST) and full-length CrkII was immobilized on glu-
tathione-agarose. Lysates from human kidney 293T cells
overexpressing Abl were passed over immobilized Crk in
the presence of peptide or peptide–peptoid compounds.
Bound proteins were separated on sodium dodecylsulfate
(SDS)–polyacrylamide gels and visualized by anti-Abl
western blotting. As shown in Figure 5, the Sos wild-type
peptide was not able to inhibit the Crk–Abl interaction
even at 100 µM concentration. But both the Crk-specific
wild–type peptide (22) and the Crk-specific Nspe
peptide–peptoid (23) were highly effective at inhibiting
Crk binding to Abl. Remarkably, compound 23 at 10 nM
concentration showed significant inhibition of the inter-
action between Crk and Abl, and at 100 nM completely
abolished binding. From the gels, we estimate the inhibi-
tion at half-maximal concentration (IC50) for compound
23 to be ~50 nM, about tenfold more effective than the
Crk-specific wild-type peptide and at least 200-fold more
effective than the Sos wild-type peptide. These data
show that the peptide–peptoid compounds are highly
effective at inhibiting natural SH3 interactions.
Peptide–peptoid activation of a Src-family kinase
Previous work has demonstrated that Src-family kinases
can be activated through SH3-mediated interactions [28].
We wanted to investigate whether the peptide–peptoid
compounds identified in our library were effective in acti-
vating Src-family kinases. The ability to selectively activate
different members of Src-family kinases would greatly aid
in understanding their roles in complex signaling pathways.
The domain topology of Src-family kinases consists of
SH3, SH2 and kinase domains [29,30]. Biochemical and
structural studies revealed that the SH3 domain helps
maintain the kinase in the repressed state by interacting
with an intramolecular proline-rich sequence. In the
crystal structures of the repressed forms of Hck and Src,
the intramolecular SH3 interaction appears to lock the
kinase domain in a catalytically incompetent state
(Figure 6a) [31,32]. Disruption of the intramolecular SH3
interaction by competing intermolecular ligands is there-
fore proposed to provide a mechanism for kinase activa-
tion. Nonetheless, small SH3 peptide ligands make poor
activators of the Src-related kinase Hck [28]. In contrast,
the intact HIV protein Nef — a 27–30 kDa protein that
has been identified as the highest affinity ligand for Hck
SH3 [33] — has been shown to potently activate the
kinase [28]. Nef binds the Hck SH3 domain through a
PxxP motif, but also has extensive tertiary interaction
extending beyond the PxxP core, which allows it to bind
with an affinity that is two orders of magnitude greater
than that of small peptides [34]. Moarefi et al. [28]
showed that the intramolecular SH3 interaction can be
outcompeted by the high-affinity Nef–SH3 interaction,
resulting in full activation of the kinase. 
We therefore wanted to test whether the small
peptide–peptoid ligands identified here were capable of
activating Src-family kinases. We chose Hck kinase as a
test case rather than Src for two reasons: first, the assays
for Hck activation were well-established; and second,
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Figure 3
Full replacement of the PxxP core without loss
in affinity. Binding isotherms for the Sos wild-
type peptide (closed circles) or compound
19 (open circles) to the N-Grb2 SH3 domain.
Required prolines are shown in red, and the
peptoid residue is designated as an ‘x’
showing the corresponding sidechain. Solid
and dashed lines show the nonlinear least-
squares fit to the data for the wild-type peptide
and compound 19, respectively. Compound
19 has only one of the starting five prolines
remaining from the Sos wild-type peptide.
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there is a natural high-affinity ligand (Nef) for Hck SH3
that has been shown to potently activate the kinase. The
published data on the affinity of Nef for the Hck SH3
and its ability to activate Hck enable a direct comparison
with the results from our peptide–peptoid studies. From
the library above, we chose several high-affinity com-
pounds and measured their affinities for the isolated Hck
SH3 domain. The best compounds were then tested for
their ability to activate full-length Hck (Figure 6b).
Selected peptides and peptide–peptoid compounds were
incubated individually in a kinase reaction with Hck and
the rate of phosphotransfer was measured as a function of
ligand concentration. The ability of a ligand to activate
Hck was quantitated as Kact, the concentration of ligand
required for half-maximal activation. We found that Kact
values correlated well with the dissociation constants of
the peptide–peptoid compounds for isolated Hck SH3
domain. The strong correlation between Kact and Kd is
Research Paper  Improving SH3 domain selectivity Nguyen et al. 469
Figure 4
Enhanced domain selectivity from combined
peptoid substitutions and specific flanking
sequences. Isotherms for the binding of
(a) Sos wild-type peptide, (b) Crk-specific
peptide, (c) Crk-specific Nnme peptide–
peptoid (compound 24) and (d) Crk-specific
Nspe–Nnme peptide–peptoid (compound 25)
to the Crk (open squares), N-Grb2 (closed
circles) and Src (open triangles) SH3
domains. Flanking sequences are underlined.
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consistent with the model that SH3 displacement is a
mechanism for kinase activation, suggesting that the level
of activation is dependent on the affinity of the SH3
domain for different PxxP containing ligands. In the best
case, the Src-specific Nspe peptide–peptoid (compound
21) activated Hck with a Kact of 7.9 µM (Figure 6c),
tenfold better than the wild-type peptide and twofold
better than GST–Nef. Thus, the much smaller peptide–
peptoid compounds can activate Src-family kinases with
comparable potency as intact protein activators. These
compounds represent important leads in the generation of
small kinase-specific activators which could prove useful
in understanding the complex roles of the various
members of this important family of kinases.
Discussion
It has been proposed that, owing to the relatively small
SH3–ligand interface (~400 Å2) and the small number of
hydrogen bonds, peptide recognition by SH3 domains is
highly promiscuous [35]. Interaction with the core PxxP
motif provides very little specificity, as the residues that
contact the core motif are highly conserved within the
SH3 family. To date, most work on ligand specificity in
SH3 recognition has focused on nonconserved residues
flanking the PxxP core. Biased combinatorial libraries,
phage-display libraries and rational mutagenesis have
been the most informative in identifying flanking
sequences that optimized interactions outside the core,
but have been less successful in achieving specificity
within the PxxP core [7,12,21,22,36].
Our results indicate that strong specificity determinants
exist within the PxxP binding core, but that these were
inaccessible to peptide and phage-display libraries. Struc-
tural studies have shown that the contacts within the PxxP
core are mediated by pairs of Cα- and N-substituted
amino acids (–xP– dipeptides) on the ligand [6,14]. Phage-
display and peptide libraries reveal that different SH3
domains have slight preferences for amino acids at the
Cα-substituted position, but they determine that the
N-substituted position is invariantly proline, simply
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Figure 5
Potent inhibition of Crk–Abl interaction by a Crk-specific
peptide–peptoid. Inhibition of Crk SH3-mediated binding to Abl by the
Sos wild-type peptide, Crk-specific wild-type peptide and Crk-specific
Nspe peptide–peptoid. Bound Abl was separated by sodium
dodecylsulphate (SDS)–PAGE and visualized by anti-Abl antibody.
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Figure 6
Activation of a Src-family kinase by peptide–peptoid compounds.
(a) Mechanism of activation of Src-family kinases by SH3
displacement according to Moarefi et al. [28]. Src-family kinases are
maintained in the repressed state by intramolecular SH3 and SH2
interactions. Displacement of the SH3 domain by a competing
intermolecular SH3 ligand results in maximal activation. (b) Activation
and dissociation constants for the peptide–peptoid compounds tested
against full-length autophosphorylated Hck kinase and the isolated Hck
SH3 domain, respectively. (c) Activation curve for the Src-specific
peptoid (compound 21) tested against Hck kinase.
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because proline it is the only available N-substituted
amino acid [21,36]. By replacing prolines with N-substi-
tuted peptoids, we have in effect increased the working
‘vocabulary’ of N-substituted residues, allowing us to
expose specificity determinants that were inaccessible to
previous studies (Figure 7). 
We can begin to assess characteristic preferences for each
SH3 domain by going to larger and more diverse peptoid
libraries. Taken together, the libraries reported here and
elsewhere [14] show, on the one hand, that the N-Grb2 SH3
domain has a strong preference for bulky aromatic peptoid
sidechains — the best ligands contain the Ndmb, Nspe and
Ndfb peptoids — and that it has a very low tolerance for
positively charged amino sidechains. On the other hand, the
Crk SH3 domain seems to be considerably more tolerant to
various polar peptoid substitutions. We used this to our
advantage to design selective ligands for Crk by choosing
sidechains that are tolerated by Crk but not by other SH3
domains. By combining such specific peptoid sidechains
with a Crk-specific flanking sequence, we have been able to
generate an inhibitor that shows orthogonal selectivity for
the Crk SH3 domain, within our test set of normally cross-
reactive SH3 domains. Development of a deeper under-
standing of peptoid preferences for individual SH3 domains
will aid in the design of directed inhibitor libraries.
We have shown that single peptoid substitutions can
have profound effects on affinity and specificity, provid-
ing a greater than 100-fold increase in affinity and a
roughly 300-fold increase in specificity. The optimization
of PxxP core interactions might result in minimized, low
molecular weight inhibitors that could still bind with
high specificity. Furthermore, we show that combina-
tions of specific peptoid substitutions and flanking
sequences identified by phage-display and peptide
libraries can enhance both affinity and specificity for SH3
interactions. Thus, by combining specificity-determining
elements from inside and outside the PxxP core, ligand
specificity can be tuned to a particular SH3 domain.
Significance
Selectively disrupting protein–protein interactions is a
principal goal of chemical biology. Src homology 3
(SH3) domains are an important class of biological
targets, as they mediate interactions in many regula-
tory pathways. The identification of selective small-
molecule inhibitors has been hampered by the fact that
SH3 domains bind their natural peptide ligands with
low affinity and with high cross-reactivity for different
domains. We have demonstrated that by replacing core
proline residues within an SH3 ligand with N-substi-
tuted glycine residues, or peptoids, and by combining
these substitutions with other specificity elements, we
can markedly increase both domain affinity and selec-
tivity. The peptoid–peptide ligands described here are
some of the most promising inhibitors against SH3
domains to date, and they represent a significant step
towards the design of small-molecule SH3 inhibitors
that could be used either to dissect signaling pathways
or as therapeutic agents targeted against diseases
arising from signaling defects.
Materials and methods
Materials
Fmoc amino acids were purchased from Novabiochem (San Diego,
Ca) or Anaspec (Santa Clara, CA). Amines were purchased from
Sigma (St. Louis, MO) or Fluka (Buchs, Switzerland) and used
without further purification. HATU was purchased from PerSeptive
Biosystems (Hamburg, Germany).
Peptoid synthesis
Peptoid-containing compounds were synthesized in parallel on a Zymark
robotic synthesizer using standard peptide and peptoid chemistry as
published elsewhere [14,16] with the following exception: to couple an
amino acid onto the peptoid residue, we used 10 equivalents Fmoc
amino acid, 10 equivalents HATU and 20 equivalents DIEA. The amino
acid was double-coupled for 4 h at room temperature. Compounds were
cleaved from resin with 88% (v/v) TFA, 5% (w/v) phenol, 5 % (v/v) H2O
and 2% (v/v) triisopropylsilane. After ether extraction, compounds were
purified by reverse-phase high performance liquid chromatography
(HPLC) and resuspended in water. Concentrations of stock solutions
were determined by tyrosine absorbance and amino acid analysis.
Protein expression and purification
SH3 proteins were expressed as glutathione-S-transferase (GST)
fusions using a modified pGEX4T-1 plasmid encoding a six-histidine
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Figure 7
Proposed mechanism for peptoid selectivity. Proline recognition
pockets of two different SH3 domains (a) and (b) nominally require
proline simply because it is the only N-substituted amino acid.
Peptoids fulfill the minimum requirement for N-substitution, but
selected peptoid sidechains are able to exploit slight variations in the
structures of different SH3 domains.
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tag at the carboxyl terminus. Proteins were expressed in TG1
Escherichia coli cells by inducing with 1 mM IPTG for 3–5 h. Cells
were harvested and sonicated and the lysates were run over a glu-
tathione-agarose column. After washing, bound proteins were cleaved
with 10 µg thrombin at 4°C overnight. Released proteins were eluted
and bound to a Ni-NTA column, washed and eluted in 100 mM sodium
phosphate pH 4, 300 mM NaCl. Purified proteins were dialyzed into
20 mM sodium acetate pH 4, 50 mM NaCl, 1 mM dithiothreitol (DTT),
and concentrated to ~5 mg/ml for storage. Proteins were typically
more than 90% pure as judged by SDS–PAGE.
Peptoid binding
Dissociation constants (Kd) were assayed by titrating increasing con-
centrations of ligand and measuring tryptophan perturbation. Assays
were performed using a Photon Technology International fluorometer
and fit by nonlinear least-squares analysis with the program
Sigmaplot or Profit as detailed elsewhere [37]. Total protein concen-
tration (P) for all experiments was fixed at 0.05–1 µM, well below the
dissociation constant for most ligands. For high affinity ligands where
Kd ≈ P, data were fit to the following equation:
Fb = (Kd + P + L ± ((Kd + P + L)2 – 4PL)1/2)/ 2P
where Fb = fraction bound and L is the total peptide ligand concentra-
tion. Data presented are the averages of at least two independent mea-
surements. Error for all measurements ranged between 5 and 20%.
Crk–Abl binding assay
The retroviral vector encoding c-Abl (pGDN-Abl) and the bacterial
expression vector encoding GST–Crk were gifts of Bruce Mayer
(Harvard Medical School). Human kidney 293 cells expressing the ade-
novirus large T antigen (293T) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum and antibiotics
and antimycotics. 293T cells (4 × 106) were seeded in 100 mm diame-
ter tissue culture dishes 24 h before transfection. Calcium phosphate
transfection was carried out according to Pear et al. [38]. Immediately
before transfection, cells were treated with 25 µM chloroquine and
cells were transfected with 0.5 ml of DNA–calcium phosphate copre-
cipitate containing 5 µg of pDGN-Abl. After 8 h incubation at 37°C, the
medium was changed and incubation was continued for another 48 h.
Cells in each plate were lysed in 1 ml of buffer containing 25 mM Tris-
–HCl pH 8.0, 140 mM NaCl, 2 mM EDTA, 1 mM Na3VO4, 1% NP40,
1 mM phenylmethylsulfonyl fluoride (PMSF), 5 µg/ml aprotinin and
2 µg/ml leupeptin, and then incubated with occasional mixing for
30 min at 4°C. The lysates were cleared by centrifugation at 12,000g
for 10 min, and the protein concentrations of the postnuclear super-
natants were determined by the Bradford method (Bio-Rad). 
GST–Crk fusion protein (1 µg) bound to glutathione-agarose beads
was pre-incubated with various concentrations of peptoid competi-
tors in 400 µl at 4°C for 10 min. Abl transfected cell lysate
(50 µl,10 µl) was added to each tube and incubated for an additional
2 h at 4°C. The glutathione-agarose beads were recovered by cen-
trifugation and washed three times in 1 ml of lysis buffer. Bound pro-
teins were fractionated by SDS–PAGE under reducing conditions
and then electrotransferred to polyvinylidene difluoride (PVDF) mem-
branes (Millipore). The membranes were blocked overnight in buffer
containing 10 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20
and 1% bovine serum albumin. The amount of Abl associated with
GST–Crk protein in each case was detected by incubation with anti-
Abl monoclonal antibody 8E9 (Pharmingen), followed by HRP-conju-
gated goat anti-mouse IgG (Amersham), and developed with
enhanced chemiluminescent (ECL) western blotting reagent accord-
ing to the manufacturer’s instructions (Amersham). 
Kinase activation assay
Down-regulated Hck was produced in Sf9 cells by co-infection with
Csk and purified as described [28]. Hck was autophosphorylated by
pre-incubation of (1–10 µM) Hck with 0.5 mM ATP for 30 min at room
temperature. SH3 ligands were pre-incubated with autophosphory-
lated Hck for 10 min. The reaction was initiated by the addition of sub-
strate peptide (Ala–Glu–Glu–Glu–Ile–Tyr–Gly–Glu–Phe–Glu–Ala–
Lys–Lys–Lys–Lys–Gly) and components of the coupled assay. Initial
rates were measured for autophosphorylated wild-type Hck by a
coupled spectrophotometric assay in which the production of ADP
was coupled to the oxidation of NADH measured as a reduction in
absorbance at 340 nm. 
The activation constant, Kact, was determined by nonlinear regression
analysis of the rates as a function of ligand concentration (SH3 binding
peptoid or peptide) using the equation, 
va = Vact[L]/(Kact + [L])
where va = velocity measured in the presence of ligand minus the
velocity measured in its absence, Vact = the maximal activated velocity
minus the velocity measured in the absence of ligand, and [L] is the
concentration of SH3 binding peptoid/peptide [39]. All Kact determina-
tions were performed at substrate concentrations of 500 µM ATP and
600 µM peptide. 
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